title: Beneficial effect of alanine on metabolic recovery of fasted livers submitted to cold ischemia.
abstract: The aim of this study was to investigate the possible beneficial effect on perfused mouse liver of alanine as an exogenous substrate for gluconeogenesis. Livers from fed and fasted animals were perfused with oxygenated Krebs' Henseleit buffer for 30 min, then stored at 4 degrees C in University of Wisconsin solution for 48 h. Then reperfusion at 37 degrees C was performed according to two protocols. In the first one, reperfusion with alanine-free Krebs' Henseleit buffer was used for 1 h. 8 mM (3-(13)C) alanine was then added and perfusion was prolonged for a second hour. In the second one, the first hour of perfusion was omitted and the organs were reperfused directly for an hour in the presence of 8 mM (3-(13)C)alanine. 31P NMR was used to measure the NTP recovery of the livers. At the end of the reperfusions, 13C and 1H NMR spectra of perfusates and of glutamine extracted from these perfusates by HPLC were recorded. These data were analysed according to a model of liver metabolism assuming that the only substrate of the liver was (3-(13)C)alanine and endogenous substrates were metabolizable only through pyruvate. It was found that in the absence of initial alanine at reperfusion, livers from fasted mice recovered less NTP than those of fed ones (40 +/- 4% vs 60 +/- 5%, p <0.01), but not if this substrate is present at the beginning of reperfusion (61 +/- 5% vs 60 +/- 5%). This was confirmed by the amount of labelled metabolites produced. However, the dilution of 13C labelled metabolites by unlabelled ones did not indicate a larger concentration of endogenous substrates in livers from fed mice. The conclusion reached was that the lower pyruvate dehydrogenase activity of livers from fasted mice relatively to that from fed mice could be compensated for by the greater pyruvate concentration provided by alanine for the initial production of NTP after cold ischemia and warm reperfusion.
authors.affiliation: U350 INSERM, Institut Curie, Centre Universitaire, Orsay, France.
authors.forename: J
authors.initials: J
authors.lastname: Patry
authors.forename: R
authors.initials: R
authors.lastname: Adam
authors.forename: Y
authors.initials: Y
authors.lastname: Blouquit
authors.forename: I
authors.initials: I
authors.lastname: Astarcioglu
authors.forename: A
authors.initials: A
authors.lastname: Dennison
authors.forename: J L
authors.initials: JL
authors.lastname: Dimicoli
authors.forename: H
authors.initials: H
authors.lastname: Bismuth
mesh_terms: D000409:Alanine / Q000627:therapeutic use*; D000818:Animals; D015925:Cryopreservation; D005215:Fasting / Q000502:physiology*; D019194:Ischemic Preconditioning / Q000379:methods*; D008099:Liver / Q000098:blood supply / Q000187:drug effects* / Q000378:metabolism; D008112:Liver Glycogen / Q000378:metabolism; D016031:Liver Transplantation / Q000379:methods / Q000502:physiology; D009682:Magnetic Resonance Spectroscopy / Q000379:methods*; D008297:Male; D051379:Mice; D009752:Nutritional Status; D010758:Phosphorus; D011522:Protons; D015424:Reperfusion; D016896:Treatment Outcome; D014280:Triglycerides / Q000378:metabolism
chemical_list: D008112:Liver Glycogen; D011522:Protons; D014280:Triglycerides; D010758:Phosphorus; D000409:Alanine